Market Analysis - (2020) Volume 5, Issue 1
We are overwhelmed to announce 3rd global experts meet on Advanced technologies in Diabetes Research and Therapy” which is going to be held during May 13-14, 2020 at Singapore.
DIABETES GLOBALLY: Diabetes is considered as the world’s fastest growing chronic condition. The type 2 diabetes is growing highly in each country. In 2013, diabetes caused 1.6 million deaths globally.
The World Diabetes Day is celebrated on November 14 each year. This day engages millions of diabetic patients worldwide in diabetes advocacy and awareness activities in response to growing concerns about the health threat that diabetes poses globally.
Diabetes 2020 Conference invites all renowned scientists, dieticians, endocrinologists, primary health care specialists, surgeons, pharmaceutical industrial delegates, radiation therapists, general physicians, talented young scientists, and student communities across the globe to attend International Diabetes congress.
The major share in endocrine testing market share is held by companies such as Abbott Laboratories, AB Sciex, Agilent Technologies, Biomedical Technologies, Biomerieux SA, Bio Rad Laboratories, DiaSorin, Hoffmann-La Roche Ltd., LabCorp, and Quest Diagnostics.
Growing incidences of endocrine disorders such as hyperthyroidism and adrenal insufficiency is predicted to boost the demand for endocrine testing. Furthermore, growing healthcare awareness among individuals coupled with increasing government support is expected to increase the diagnosis at an early, thereby contributing to the growth of the endocrine testing market.
The players are actively involved in launching technologically advanced products and initiate collaborative developments to sustain themselves in the competition. For instance, LabCorp offers all-embracing solutions on clinical trials pertaining to diabetes and all other hormonal diseases.
The global Next Generation Diabetes Therapy And Drug Delivery Market generated $1.25 billion in 2017 and is estimated to reach $9.67 billion by 2023, growing at a CAGR of 40.6% from 2018 to 2023. The report offers a detailed analysis of changing market trends, key investment pockets, major segments, geographical regions, and competitive scenario.
The CGM systems segment accounted for more than nine-tenths of the total revenue in 2017 and will maintain its dominance by 2023. This is due to various benefits including ease of usability and detection of levels of blood glucose. The report also explores inhalable insulin, oral insulin, and artificial pancreas.
Diabetes Meeting 2020 will feature the latest developments in research, diagnosis and prevention of diabetes, new insulin analogues, new technologies and devices for diabetes.
The Editors will concentrate on studies that involve wisely selected reports that provide a link between basic research and translation to diabetes-related diseases. The editors support the diffusion of distinctive solutions to challenging scientific and translational questions related with studies of Diabetes and metabolically/genetically related disorders.
Presumably, scientists in all disciplines related to Diabetes and various scientists devoted to Glucose Metabolic Homeostasis and related subjects will engage as authors of JDRT articles. Most likely those studies would be focused on indicators of disease risk and mechanisms of glucose metabolic dysregulation related diseases.
1. Journal of endocrinology Research
2. Journal of Genetic Disorders & Genetic Reports
Emili Sherlyn| Program Manager
Phone: + 442039365603-5081
Email id: [email protected]
Published Date: Mar 16, 2020
Copyright: This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.